ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin ‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)
Cancer, EarlyView.
Source: Cancer - Category: Cancer & Oncology Authors: Daniel Morgensztern,
Manuel Cobo,
Santiago Ponce Aix,
Pieter E. Postmus,
Conrad R. Lewanski,
Jaafar Bennouna,
J ürgen R. Fischer,
Oscar Juan‐Vidal,
David J. Stewart,
Gianpiero Fasola,
Andrea Ardizzoni,
Rafia Bhore,
Marianne Wolfsteiner,
De Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Nanotechnology | Non-Small Cell Lung Cancer | Study